• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Japanese universal health care faces a crisis in cancer treatment.

作者信息

Fujiwara Yasuhiro, Yonemori Kan, Shibata Taro, Okita Natsuko, Ushirozawa Nobuko

机构信息

Office of Advanced Medical Care Evaluation, National Cancer Center, Tokyo, Japan; Strategic Planning Bureau, National Cancer Center, Tokyo, Japan; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Office of Advanced Medical Care Evaluation, National Cancer Center, Tokyo, Japan; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Lancet Oncol. 2015 Mar;16(3):251-2. doi: 10.1016/S1470-2045(15)70007-0.

DOI:10.1016/S1470-2045(15)70007-0
PMID:25752548
Abstract
摘要

相似文献

1
Japanese universal health care faces a crisis in cancer treatment.日本的全民医保在癌症治疗方面面临危机。
Lancet Oncol. 2015 Mar;16(3):251-2. doi: 10.1016/S1470-2045(15)70007-0.
2
Health policy: Putting a price on cancer.卫生政策：为癌症定价。
Nat Rev Clin Oncol. 2016 Mar;13(3):137-8. doi: 10.1038/nrclinonc.2016.12. Epub 2016 Feb 9.
3
Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.价值的多个维度：新型癌症疗法的评估框架
J Clin Oncol. 2016 Apr 20;34(12):1428-9. doi: 10.1200/JCO.2015.66.4201. Epub 2016 Feb 16.
4
[Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].评估药物的有效性。“一种疗法的全部潜力往往要经过数年才会明晰”（赫尔穆特·拉舍特访谈）
MMW Fortschr Med. 2010 Dec 16;152(51-52):10.
5
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.致癌靶点、获益程度和抗肿瘤药物的市场定价。
J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23.
6
[Clinical studies in oncology--a challenge for clinical and academic pathology].[肿瘤学临床研究——临床与学术病理学面临的一项挑战]
Dtsch Med Wochenschr. 2013 May;138(20):1073-6. doi: 10.1055/s-0033-1343111. Epub 2013 May 13.
7
Resistance and change: a multiple streams approach to understanding health policy making in Ghana.阻力与变革：一种理解加纳卫生政策制定的多源流方法
J Health Polit Policy Law. 2015 Feb;40(1):195-219. doi: 10.1215/03616878-2854711. Epub 2014 Dec 5.
8
[The health care debate in USA hits the core of the American self comprehension].美国的医保辩论触及了美国人自我认知的核心。
Ugeskr Laeger. 2009 Oct 26;171(44):3150.
9
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.美国食品药品监督管理局扩大治疗用研究性药物可及性的拟议法规：打着改革幌子的现状。
Food Drug Law J. 2009;64(1):183-223.
10
[Universal Health Coverage and Cancer Drugs - A Cost-Effectiveness Perspective].[全民健康覆盖与抗癌药物——成本效益视角]
Gan To Kagaku Ryoho. 2016 Nov;43(11):1311-1315.

引用本文的文献

1
Mission of the National Cancer Center Hospital in Japan to promote clinical trials for precision medicine.日本国立癌症中心医院推动精准医学临床试验的使命。
Cancer Biol Med. 2023 Feb 28;21(1):1-3. doi: 10.20892/j.issn.2095-3941.2022.0643.
2
Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China.非小细胞肺癌中新兴的PD-1/PD-L1靶向免疫疗法：日本、美国、欧盟及中国的现状与未来展望
Front Oncol. 2022 Aug 26;12:925938. doi: 10.3389/fonc.2022.925938. eCollection 2022.
3
Impact of a reduction in follow-up frequency on life expectancy in uterine cervical cancer patients.
随访频率降低对宫颈癌患者预期寿命的影响。
Int J Clin Oncol. 2020 Jun;25(6):1170-1177. doi: 10.1007/s10147-020-01641-w. Epub 2020 Mar 9.
4
Advanced Medical Care Program for the Rapid Introduction of Healthcare Technologies to the National Health Insurance System in Japan.日本医疗技术快速纳入国民健康保险制度的高级医疗保障计划。
Clin Transl Sci. 2020 Jul;13(4):700-706. doi: 10.1111/cts.12751. Epub 2020 Feb 27.
5
Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan.新流程在未获批药物使用中的应用：日本全民医保覆盖面临的困境
J Glob Oncol. 2019 Nov;5:1-3. doi: 10.1200/JGO.19.00313.
6
Compassionate use of drugs and medical devices in the United States, the European Union and Japan.美国、欧盟和日本药品及医疗器械的同情用药情况。
Regen Ther. 2016 Feb 15;4:18-26. doi: 10.1016/j.reth.2015.11.002. eCollection 2016 Jun.
7
Comparison of acute vertigo diagnosis and treatment practices between otolaryngologists and non-otolaryngologists: A multicenter scenario-based survey.耳鼻喉科医生与非耳鼻喉科医生在急性眩晕诊治实践中的比较：一项基于多中心情景的调查。
PLoS One. 2019 Mar 7;14(3):e0213196. doi: 10.1371/journal.pone.0213196. eCollection 2019.
8
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.在临床环境中检测 114 个癌症相关基因的面板的可行性和实用性：一项基于医院的研究。
Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2.
9
A call for improved transparency in financial aspects of clinical trials: a case study of the CREATE-X trial in the New England Journal of Medicine.呼吁提高临床试验财务透明度：以《新英格兰医学杂志》中的 CREATE-X 试验为例。
Invest New Drugs. 2018 Jun;36(3):517-522. doi: 10.1007/s10637-018-0577-x. Epub 2018 Mar 8.
10
Implementation of "clinical sequencing" in cancer genome medicine in Japan.日本癌症基因组医学中“临床测序”的实施情况。
Cancer Sci. 2018 Mar;109(3):507-512. doi: 10.1111/cas.13486. Epub 2018 Feb 2.